Diag2Tec has privileged access to a large collection of patient-derived primary samples with various hematologic malignancies, including newly diagnosed and relapsed cases, available for ex vivo assay. These samples are from different origins (bone marrow, blood, tissues), and preserve the biological complexity and heterogeneity observed in patients, providing a unique opportunity to assess drug responses in clinically meaningful contexts.
Diag2Tec has privileged access to a large collection of patient-derived primary samples with various hematologic malignancies, including newly diagnosed and relapsed cases, available for ex vivo assay. These samples are from different origins (bone marrow, blood, tissues), and preserve the biological complexity and heterogeneity observed in patients, providing a unique opportunity to assess drug responses in clinically meaningful contexts. As most of primary samples have been thoroughly characterized using RNA-seq from bulk or isolated-tumor cells, and are fully annotated with clinical data (age, gender, cytogenetics, subtypes, history of treatment), Diag2Tec can select the best models to meet specific needs. All primary samples or data are used after patient’s declared consent and following approval of the Ethic Committee. Our partner Biological Resources Centers are certified ISO9001 and ISO 20387.
Mechanistic and Functional Readouts
We generate actionable data through the co-culture of primary samples within their microenvironment :
- Deep phenotyping and immune profiling by multiparametric flow cytometry,
- Ex vivo drug sensitivity profiling (single treatments and combination) with treatment ranging from 24 hours to up to 10 days (20 to 100 conditions depending on models and readouts)
- Evaluation of cytotoxicity and depletion of tumor and non-tumor cells (multiparametric flow cytometry),
- Customized assays with co-culture systems depending of the needs,
- Specific immune-mediated assays (ADCC, ADCP, CDC, Bispecific),
- Cytokines and other soluble factors analyses (Elisa, Proteomic assays)
- Genomic characterization at baseline and/or after treatments,
- Integration with clinical, biological, and multi-omics datasets.
Our resources enables the evaluation of therapeutic agents across a wide range of patient profiles, including resistant and refractory settings. This approach supports the identification of differential responses, mechanisms of resistances, and strategies to overcome them, including resensitization through combination therapies.
Deliverables
High-quality, decision-ready data packages including comprehensive reports and raw/processed datasets, supporting translational research and precision medicine approaches